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Objectives: The 21-gene Breast Cancer Test (Oncotype DX®) is a validated diag-
nostic test that predicts the likelihood of adjuvant chemotherapy benefit and breast 
cancer recurrence in selected patients with early-stage breast cancer. A previous 
cost-effectiveness analysis of this test versus standard French clinical practice was 
published in 2012. Since then, docetaxel is no longer reimbursed on top of the 
diagnosis related groups (DRGs). The objective of this study was to update the cost-
effectiveness analysis considering this change. MethOds: The cost-effectiveness 
analysis was conducted using a Markov model including three health states (sur-
vival without recurrence, metastatic recurrence at ten years and death). Previous 
cost analyses were updated in order to assess the current overall costs of chemo-
therapy in public and private hospitals, considering that doxetaxel is not anymore 
reimbursed on top of DRGs. Unit costs were updated to 2015 values and other model 
parameters were collected from published literature. This study was conducted 
from the societal perspective. Deterministic sensitivity analyses were conducted to 
identify key drivers of the results. Results: Chemotherapy costs (standard devia-
tion) per patient were estimated at € 10,917 from the societal perspectivein public 
hospitals. The incremental number of life years gained over 30 years was 0.15; the 
incremental number of QALYs gained was 0.14. Using the test was found to be cost-
effective versus usual care with a cost per QALY ratio of € 3,453 in public hospitals 
(€ 4,147 in private) from public perspective and a dominant strategy with a net cost-
saving per patient of € 658 in public hospitals (€ 449 in private) when considering 
costs of absenteeism. cOnclusiOns: While the cost of chemotherapy decreased 
considerably after the inclusion of docetaxel in the DRGs, the use of the 21-gene test 
is still cost-effective compared to usual care in French public and private hospitals 
from a societal perspective.
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Objectives: To conduct a cost-effectiveness analysis of primary and second-
ary prophylaxis (PP & SP) with long acting granulocyte colony-stimulating fac-
tors (G-CSFs), such as pegfilgrastim, lipegfilgrastim, and short acting G-CSFs (i.e. 
filgrastim or lenograstim used in a 6-day regimen) for chemotherapy-induced 
febrile neutropenia (FN) in patients with non-Hodgkin’s Lymphoma (NHL) in 
Greece. MethOds: An economic model that comprises a decision tree and a Markov 
chain, consisting of two phases, was locally adapted to reflect outcomes from payer 
perspective. The analysis was conducted for a lifetime horizon, across two different 
chemotherapy schemes (CHOP and CHOP-R). Clinical inputs included baseline FN 
risks, efficacy of G-CSFs, mortality, effects of FN on relative dose intensity, as well 
as direct medical costs for drug acquisition and administration and FN manage-
ment. Input values were extracted from published studies while those for costs 
(2015 EUD) were obtained from local resources. Model outcomes were FN events 
avoided, and treatment strategies were compared by calculating incremental cost-
effectiveness ratios (ICERs) per FN event avoided. Results: PP with pegfilgrastim 
provided greater health benefits in terms of FN events (calculated by combining FN 
risk with the efficacy of G-CSFs: 0.164) followed by PP with lipegfilgrastim (0.243) 
and SP with pegfilgrastim (0.522). PP with pegfilgrastim was cost-effective versus 
SP with pegfilgrastim across all chemotherapy schemes (ICERs of € 7,490 for CHOP 
and € 7,781 for CHOP-R). SP with pegfilgrastim was cost-effective compared to SP 
with filgrastim (ICERs of € 1,657 for CHOP and € 1,836 for CHOP-R). SP with filgrastim 
was cost-effective compared to no prophylaxis (ICERs of € 1,404 for CHOP and € 1,585 
for CHOP-R). The rest of the alternatives were dominated by a less expensive and 
more effective strategy. cOnclusiOns: Our analysis finds PP with pegfilgrastim to 
be a cost-effective option for chemotherapy-induced FN in NHL patients in Greece.
PCN157
Cost-EffECtivENEss iN thE sECoNd-liNE trEAtmENt of NoN-smAll CEll 
luNG CANCEr (NsClC) iN thE us
Graham C1, Knox H1, Hess LM2, Jen M2, Cuyun Carter G2, Chandrawansa K2, Boye M2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly, Indianapolis, IN, USA
Objectives: The objective of this study was to develop a cost-effectiveness model 
from a third-party payer perspective to evaluate second-line treatment strate-
gies for NSCLC in the US and to investigate the value of ramucirumab+docetaxel 
(RAM+DOC) across histological subtypes. MethOds: Model comparators include 
the most commonly used second-line treatment regimens for NSCLC for which clini-
cal trial data were available in the squamous, nonsquamous, and overall population. 
We used a lifetime horizon, 3% cost discounting rate, and semi-Markov structure to 
account for time-dependent variation in probabilities of progression-free and overall 
survival. The structure of the model incorporated 21-day cycles and four health 
states including second-line treatment, third-line treatment, best supportive (pallia-
tive) care, and death. Clinical trial data were supplemented by other published data, 
when necessary. Probabilistic and one-way sensitivity analyses were conducted to 
test the robustness of findings. Results: Based on the results of this cost-effec-
tiveness analysis, RAM+DOC in the second-line treatment of patients may be con-
sidered a cost-effective option in the nonsquamous populations given an oncology 
willingness-to-pay threshold of $200,000 per life-year gained (ICER= $192,833 versus 
docetaxel alone). For the overall NSCLC population, comparators were limited and 
the incremental cost effectiveness ratio was slightly higher (ICER= $222,224 versus 
docetaxel). There were very limited data to evaluate the squamous population, and 
the ICER for RAM+DOC was high. The lack of complete data in the histological 
subgroups was a limitation; analyses were only possible for a subset of the com-
parators of interest. cOnclusiOns: The treatment patterns and cost data used to 
assumed to be a 50 year-old woman with HER2-positive metastatic breast cancer. 
Transition probability of each state in the model was estimated on the basis of the 
CLEOPATRA. As utility scores of Japanese metastatic breast cancer patients were not 
available, data from the NICE STA submission report were used. Costs were estimated 
on the basis of Japanese medical fee. Since our analysis was from the perspective of 
healthcare payer, only direct medical costs were included. Outcomes were meas-
ured in quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio 
(ICER) was calculated. Two percent annual discount rate was used both for costs and 
outcome. The model used a time horizon of 25 years. Results: Additional pertu-
zumab in combination with trastuzumab and docetaxel can gain more QALY (on 
average 0.85 QALY) than trastuzumab and docetaxel therapy. ICER of pertuzumab 
compared with control estimated to be about JPY 17 million per QALY (around £ 90,000, 
£ 1 = JPY 190). cOnclusiOns: Pertuzumab in combination with trastuzumab and 
docetaxel is not cost-effective in our analysis, when £ 50,000 or less is judged to be 
cost-effective as ICER.
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Objectives: To assess the cost-utility of first-line nilotinib vs imatinib in patients 
with chronic myeloid leukaemia (CML) eligible to start the treatment-free remis-
sion (TFR) phase in the Italian healthcare setting (NHS). MethOds: A previous 
cost-utility model, simulating a cohort of 20,000 patients individually followed, 
was adapted to the Italian NHS. CML patients could start treatment with nilotinib 
or imatinib while for both arms a second-line with nilotinb is expected according to 
the Italian clinical practice. Patients remaining on first-line at thirty-six months and 
with a BCR-ABL score less than MR4.5 are considered long-term responders and may 
enter the treatment free remission (TFR) phase. Model outcomes are expressed in 
Quality-Adjusted-Life-Years (QALYs) and life-years-gained (LYG). Clinical data were 
derived from ENEST-nd trial. A panel of experts in CML treatment provided input 
on healthcare resource consumption: routine visits, laboratory/instrumental tests, 
adverse events management and drug consumption. Costs - Euros (€ ) 2015 - were 
quantified using Hospital National Tariffs and ex-factory drug prices. The model 
assumes that generic imatinib and nilotib become available as of January 2017 
and July 2023,respectively, and therefore a 74% price discount for both drugs was 
included. Costs and outcomes were discounted at 3% according to Italian Guidelines 
for Economic Evaluations. Incremental cost-effectiveness ratios (ICERs) were calcu-
lated to estimate the incremental cost of a TFR patient with nilotinib. Results: An 
incremental number of 3,773 patients are eligible to TFR with nilotinib vs imatinib 
with € 33,748 total costs/patient. An improvement of +1.06 QALYs and +1.49 LYG is 
also observed in the nilotinib arm. The ICERs for nilotinib vs imatinib are € 39,935/
QALY and € 31,969/LYG. cOnclusiOns: The model shows that a greater number of 
patients enter TFR with nilotinib with acceptable ICERs vs imatinib.
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Objectives: A new human papillomavirus (HPV) vaccine protects against the 9 
HPV types responsible for 90% of HPV-related cancers (cervix, anus, vulva, vagina). It 
includes the 4 types contained in the quadrivalent (HPV 6,11,16,18) and 5 additional 
high-risk HPV types (HPV 31, 33, 45, 52, 58). The analysis aimed at estimating the 
incremental public health impact and cost-effectiveness of 2 different interven-
tions in Italy: 1) girl vaccination with a ninevalent HPV vaccine compared to a 
quadrivalent vaccine; 2) universal (girls and boys) vaccination programme with a 
ninevalent HPV vaccine compared to a quadrivalent vaccine. MethOds: A dynamic 
transmission model including a wide range of health and cost outcomes related to 
cervical, anal, vulvar, vaginal diseases and genital warts was calibrated to Italian epi-
demiological data. The clinical impact due to the 5 new types was included for cervi-
cal diseases only, producing conservative outcomes. In the base case, a two-dose 
schedule, lifelong vaccine type-specific protection and a vaccination coverage rate of 
71% for the 12-year old cohorts were assumed. A threshold of 30,000€ /QALY-gained 
was considered. Different prices assumptions were used for the ninevalent vaccine 
(from 0% to 40% higher than that of the quadrivalent HPV vaccine). Deterministic 
sensitivity analyses on key parameters (such as duration of protection, discount 
rate) were conducted. Results: Over 100 years, between 21,000 to 22,000 cervical 
cancers and between 272,600 and 288,790 pre-cancerous cervical lesions could be 
avoided with the implementation of a ninevalent vaccine. The cost-effectiveness 
ratio of the ninevalent vaccine is estimated to remain well below the threshold with 
all the different price assumptions considered. cOnclusiOns: Both scenarios with 
a ninevalent vaccine in Italy are estimated to be from cost saving to highly cost-
effective across a range of sensitivity analyses and are expected to further reduce 
the public health burden of HPV-related cancers and diseases.
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